A Randomized Control Trial of Ravulizumab for Treatment of Patients With COVID-19 Infection and Kidney Injury
| dc.contributor.author | Memon, Aliza A. | |
| dc.contributor.author | Ahmed, Hasban | |
| dc.contributor.author | Li, Yi | |
| dc.contributor.author | Wongboonsin, Janewit | |
| dc.contributor.author | Hundert, Joshua | |
| dc.contributor.author | Benoit, Stefanie | |
| dc.contributor.author | Chaudhari, Advika | |
| dc.contributor.author | Sher, Jawad | |
| dc.contributor.author | Ghimire, Pratima | |
| dc.contributor.author | Hopkins, Rebecca | |
| dc.contributor.author | Patel, Jay | |
| dc.contributor.author | Stegman, Melinda | |
| dc.contributor.author | Lim, Kenneth | |
| dc.contributor.author | Azzi, Jamil | |
| dc.contributor.author | Siedlecki, Andrew M. | |
| dc.contributor.department | Medicine, School of Medicine | |
| dc.date.accessioned | 2023-08-30T10:14:07Z | |
| dc.date.available | 2023-08-30T10:14:07Z | |
| dc.date.issued | 2022 | |
| dc.eprint.version | Final published version | |
| dc.identifier.citation | Memon AA, Ahmed H, Li Y, et al. A Randomized Control Trial of Ravulizumab for Treatment of Patients With COVID-19 Infection and Kidney Injury. Kidney Int Rep. 2022;7(12):2714-2717. doi:10.1016/j.ekir.2022.09.003 | |
| dc.identifier.uri | https://hdl.handle.net/1805/35221 | |
| dc.language.iso | en_US | |
| dc.publisher | Elsevier | |
| dc.relation.isversionof | 10.1016/j.ekir.2022.09.003 | |
| dc.relation.journal | Kidney International Reports | |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | en |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | PMC | |
| dc.subject | COVID-19 | |
| dc.subject | SARS-CoV2 | |
| dc.subject | Acute kidney injury | |
| dc.subject | Hemodialysis | |
| dc.subject | Thrombotic microangiopathy | |
| dc.title | A Randomized Control Trial of Ravulizumab for Treatment of Patients With COVID-19 Infection and Kidney Injury | |
| dc.type | Article |